News & Updates

Semaglutide trims down weight in patients with severe obesity

12 Jan 2024 by

Use of semaglutide 2.4 mg results in substantial weight reduction in patients with severe obesity who had previously undergone bariatric surgery (BS) but failed to achieve satisfactory weight loss, reports a recent study.

Semaglutide trims down weight in patients with severe obesity

12 Jan 2024

Long-term use of GH therapy safe in decompensated cirrhosis

12 Jan 2024

It is safe to use long-term growth hormone (GH) therapy in patients with decompensated cirrhosis (DC), suggests a study, noting improvements in malnutrition and even quality of life (QoL). However, 12-month survival does not seem to improve.

Long-term use of GH therapy safe in decompensated cirrhosis

12 Jan 2024

New models predict skeletal muscle mass reduction with calorie restriction

11 Jan 2024

A recent study has shown that healthy men and women with overweight or obesity who undergo voluntary calorie restriction (CR), without a structure exercise program, attain decreases in skeletal muscle (SM) mass of approximately 2 to 2.5 kg and 1 to 1.5 kg per 10-kg weight loss, respectively.

New models predict skeletal muscle mass reduction with calorie restriction

11 Jan 2024

NIH study: Semaglutide associated with lower risk of suicidal ideation

11 Jan 2024 by

Semaglutide is associated with a 49─73 percent lower risk of suicidal ideation vs other agents for treatment of obesity and type 2 diabetes mellitus (T2DM), a National Institutes of Health (NIH)─funded study has shown.

NIH study: Semaglutide associated with lower risk of suicidal ideation

11 Jan 2024

Accrued physical activity may have positive effects on weight, adiposity in overweight adults

10 Jan 2024

Some adults who are either obese or overweight tend to see themselves as less physically active than they actually are, suggests a study. However, accumulating at least 150 min/wk of moderate-to-vigorous physical activity (MVPA) can already provide benefits on a person’s weight and adiposity status.

Accrued physical activity may have positive effects on weight, adiposity in overweight adults

10 Jan 2024

Aspirin reduces liver fat, improves markers of inflammation, fibrosis

04 Jan 2024 by

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – previously called nonalcoholic fatty liver disease (NAFLD) – but without cirrhosis, who were treated with daily low-dose aspirin, had significant reductions in liver fat for 6 months in a new trial.

Aspirin reduces liver fat, improves markers of inflammation, fibrosis

04 Jan 2024

Shifting to a plant-based diet may be key to better cardiometabolic health

27 Dec 2023 by

A systematic review and meta-analysis of prospective studies demonstrate that switching from animal-based (AB) to plant-based (PB) foods conferred cardiometabolic improvements.

Shifting to a plant-based diet may be key to better cardiometabolic health

27 Dec 2023

Faecal matter transplant exerts no beneficial effect on cardiometabolic risk factors

23 Dec 2023

Faecal microbiota transplantation (FMT) does not appear to have any significant effect on the cardiometabolic parameters of individuals with at least one cardiometabolic issue, according to the results of a systematic review and meta-analysis.

Faecal matter transplant exerts no beneficial effect on cardiometabolic risk factors

23 Dec 2023

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

23 Dec 2023

Treatment with metformin plus insulin early in pregnancy for women with pre-existing type 2 diabetes (T2D) or gestational diabetes falls short of reducing the risk of adverse neonatal outcomes, as shown in the MOMPOD study.

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

23 Dec 2023

Somapacitan safe, effective in children with growth hormone deficiency

21 Dec 2023 by

Use of somapacitan, a long-acting growth hormone (GH) derivative, for 2 years is efficacious and well tolerated in prepubertal children with GH deficiency (GHD), reports a study.

Somapacitan safe, effective in children with growth hormone deficiency

21 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

Semaglutide trims down weight in patients with severe obesity

Semaglutide trims down weight in patients with severe obesity

Long-term use of GH therapy safe in decompensated cirrhosis

Long-term use of GH therapy safe in decompensated cirrhosis

New models predict skeletal muscle mass reduction with calorie restriction

New models predict skeletal muscle mass reduction with calorie restriction

NIH study: Semaglutide associated with lower risk of suicidal ideation

NIH study: Semaglutide associated with lower risk of suicidal ideation

Accrued physical activity may have positive effects on weight, adiposity in overweight adults

Accrued physical activity may have positive effects on weight, adiposity in overweight adults

Aspirin reduces liver fat, improves markers of inflammation, fibrosis

Aspirin reduces liver fat, improves markers of inflammation, fibrosis

Shifting to a plant-based diet may be key to better cardiometabolic health

Shifting to a plant-based diet may be key to better cardiometabolic health

Faecal matter transplant exerts no beneficial effect on cardiometabolic risk factors

Faecal matter transplant exerts no beneficial effect on cardiometabolic risk factors

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

Somapacitan safe, effective in children with growth hormone deficiency

Somapacitan safe, effective in children with growth hormone deficiency